Sustained, Controlled Drug Delivery To The Eye

By Harsh Patel, PhD, Cyonna Holmes, PhD, and Brian Wilson, PhD, Celanese

Chronic eye diseases are a leading cause of blindness and low vision, and current treatment approaches have limitations in terms of patient adherence and bioavailability. To improve treatment options for chronic eye conditions, sustained-release delivery options for small molecules, biologics, and RNA are needed.

Celanese's VitalDose EVA platform offers a promising solution for controlled and continuous drug release in the eye. By using polymeric implantable drug delivery systems, this platform provides advantages such as improved bioavailability, reduced variability in patient compliance, and mitigation of issues associated with repeated injections. The biodurable ocular implants made from biocompatible thermoplastics can provide tunable drug release, innovative shapes for customized delivery options, and dual functionality when incorporated into existing medical devices.

One of the key advantages of the VitalDose EVA platform is its ability to achieve tailored release profiles. The tunability of both the core and membrane components allows for the release of multiple molecules through separate mechanisms. This targeted delivery can be achieved by placing the implant in close proximity to the targeted region, increasing therapeutic bioavailability. Additionally, biodurable implants can be placed in unique locations within the eye, such as the suprachoroidal space, for the treatment of ocular posterior segment diseases.

Celanese's VitalDose EVA platform offers a promising solution for the treatment of chronic eye disorders. By providing improved drug delivery options, Celanese aims to reduce treatment burden, improve patient adherence, and enhance bioavailability in the field of ocular drug delivery.